Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...
Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...
KENNIDEE Cox started her weight loss jab journey just over a year ago and has already seen her figure transformed. But the ...
Clinical Trials Arena on MSN
Wave Life Sciences’ obesity siRNA shows “once or twice-yearly” potential
In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...
Exclusive: Australian doctors are being approached every day by teenagers and young adults – girls as well as boys – asking ...
GlobalData on MSN
GLP-1RA microdosing trend continues despite “anecdotal evidence”
"GLP-1RA microdosing trend continues despite “anecdotal evidence”" was originally created and published by Pharmaceutical ...
An expert said weight loss drugs might help people see faster results, which can give them encouragement to continue. But he ...
Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical performance and early entry advantage.
Novo Nordisk today announced new data on the investigational oral semaglutide 25 mg will be among 23 abstracts to be ...
Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...
A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...
The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results